Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer

Description:

The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer. The current gold standard multiparametric magnetic resonance imaging (mpMRI) is used to guide targeted prostate biopsies for initial diagnostic work up and for definitive focal dose-escalated radiotherapy in intermediate and high-risk prostate cancer patients. However, mpMRI might underestimate the tumor volume and manual gross tumor volume delineation based on mpMRI underlies significant interobserver variability. Thus, novel imaging modalities are warranted to increase the detection rate and/or decrease the interobserver variability during tumor delineation. This study will prospectively compare two promising advanced medical imaging methods: MRI-RSI and PSMA PET with the current gold-standard mpMRI for tumor detection and delineation in primary prostate cancer patients.

Sponsor:

Unknown Organization

Phase:

N/A

Contacts:

CONSTANTINOS ZAMBOGLOU, DR (CONTACT)

kristis.vevis@goc.com.cy

+35725208000

18F-PSMA1007

Isotope(s):
Target(s):
  • PSMA
Inclusion
  • MRI-targeted biopsy on PIRADs v2.1 lesion ≥3 performed \<6 months
  • PSMA-PET/CT-hybrid imaging performed \<3 months
  • Newly diagnosed and histologically confirmed primary prostate cancer
Exclusion
  • TUR-P of the prostate \<1 year ago
  • Previous radiation therapy to the pelvis
  • ADT or ADT + other systemic therapy before inclusion
  • Initial PSA \>100 ng/ml
  • No visible tumor on PSMA PET and mpMRI (defined by PIRADs v2.1 ≤2 lesion)